Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.
You may also be interested in...
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.
Pfizer has been unsuccessful in its appeal against the health technology assessment body’s rejection of the rare heart disease drug, Vyndaqel. Meanwhile, Dr Falk Pharma has received the all-clear to make Jorveza (budesonide) available on the National Health Service for eosinophilic esophagitis.